β-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives

Area of Science:

• Pulmonary Medicine
• Cardiology
• Pharmacology

Background:

• Coexistence of chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) poses treatment challenges.
• Beta-adrenoceptor (β-AR) modulation is critical, with inhaled β(2)-AR agonists posing risks and β-AR blockers traditionally contraindicated in COPD.
• Concerns include bronchospasm and airway hyperresponsiveness with β-AR blockers.

Purpose of the Study:

• To review the evolving understanding of β-AR modulation in COPD.
• To examine the safety and potential benefits of β-AR blockers in COPD patients with comorbid CVD.
• To discuss future therapeutic possibilities and unresolved questions.

Main Methods:

• Review of existing literature on β-AR modulation in COPD and CVD.
• Analysis of evidence regarding the safety and efficacy of β-AR blockers in COPD.
• Discussion of β-AR blockade, cardioselectivity, and potential mechanisms of action.

Main Results:

• β-AR blockers may be safe and offer benefits in COPD beyond cardiovascular protection.
• Evidence suggests a potential positive impact of β-AR blockers on COPD outcomes.
• Understanding of β-AR agonist and antagonist roles in COPD/CVD is advancing.

Conclusions:

• β-AR blockers represent a potentially valuable therapeutic option for COPD patients with CVD.
• Further research is needed to fully elucidate the benefits and mechanisms of β-AR blockers in COPD.
• The therapeutic landscape for managing comorbid COPD and CVD is evolving.